Endocrinology, Vol 131, 2717-2722, Copyright © 1992 by Endocrine Society

ARTICLES

In vivo growth hormone treatment stimulates secretion of very low density lipoprotein by the isolated perfused rat liver

MB Elam, HG Wilcox, SS Solomon and M Heimberg
Veterans Administration Hospital Research Service, Memphis, Tennessee.

We have previously demonstrated in hepatocyte suspensions prepared after in vivo GH deprivation [hypophysectomy (hypox)] that rates of esterification of [1-14C]oleic acid into triglyceride (TG) and phospholipid (PL) were diminished, and that these esterification rates were correspondingly restored by repletion with recombinant GH. The current studies were designed to determine if GH exerts a similar effect on the secretion of very low density lipoprotein (VLDL), the primary plasma carrier of TG. We assessed rates of secretion of VLDL lipid and apoprotein by perfused livers prepared from cortisol/T3- replaced hypox female rats in the presence and absence of recombinant human (h) GH infusion. We also determined rates of synthesis and secretion of VLDL TG from infused [1-14C]oleic acid. After hypox, rates of secretion of VLDL lipid (TG, PL, and cholesterol) and apoprotein (total) were significantly decreased. In addition, VLDL secreted under these conditions was depleted of PL, relative to the other lipid components. Secretion of newly synthesized VLDL TG from [1-14C]oleic acid was also decreased; however, neither intracellular accumulation of labeled TG nor absolute tissue levels of TG were significantly changed. Conversely, GH treatment of hypox rats effectively restored rates of secretion of VLDL TG, PL, cholesterol (C) and apoprotein to control levels. These findings support the putative role of GH in regulating VLDL secretion in vivo by demonstrating that alterations in plasma GH are accompanied by changes in VLDL secretion. The findings further suggest that GH may regulate VLDL secretion by altering the amount of PL and/or apoprotein available for formation of the VLDL particle.

This article has been cited by other articles:

				C. Franco, J. Brandberg, L. Lonn, B. Andersson, B.-A. Bengtsson, and G. Johannsson Growth Hormone Treatment Reduces Abdominal Visceral Fat in Postmenopausal Women with Abdominal Obesity: A 12-Month Placebo-Controlled Trial J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1466 - 1474. [Abstract] [Full Text] [PDF]

				C. Ameen, D. Linden, B.-M. Larsson, A. Mode, A. Holmang, and J. Oscarsson Effects of gender and GH secretory pattern on sterol regulatory element-binding protein-1c and its target genes in rat liver Am J Physiol Endocrinol Metab, December 1, 2004; 287(6): E1039 - E1048. [Abstract] [Full Text] [PDF]

				K.-C. Leung, G. Johannsson, G. M. Leong, and K. K. Y. Ho Estrogen Regulation of Growth Hormone Action Endocr. Rev., October 1, 2004; 25(5): 693 - 721. [Abstract] [Full Text] [PDF]

				C. Ameen and J. Oscarsson Sex Difference in Hepatic Microsomal Triglyceride Transfer Protein Expression Is Determined by the Growth Hormone Secretory Pattern in the Rat Endocrinology, September 1, 2003; 144(9): 3914 - 3921. [Abstract] [Full Text] [PDF]

				B. Olsson, M. Bohlooly-Y, O. Brusehed, O. G. P. Isaksson, B. Ahren, S.-O. Olofsson, J. Oscarsson, and J. Tornell Bovine growth hormone-transgenic mice have major alterations in hepatic expression of metabolic genes Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E504 - E511. [Abstract] [Full Text] [PDF]

				F. Frick, D. Linden, C. Ameen, S. Eden, A. Mode, and J. Oscarsson Interaction between growth hormone and insulin in the regulation of lipoprotein metabolism in the rat Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E1023 - E1031. [Abstract] [Full Text] [PDF]

				F. Frick, M. Bohlooly-Y, D. Linden, B. Olsson, J. Tornell, S. Eden, and J. Oscarsson Long-term growth hormone excess induces marked alterations in lipoprotein metabolism in mice Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1230 - E1239. [Abstract] [Full Text] [PDF]

				J. M. Fitts, R. M. Klein, and C. A. Powers Estrogen and Tamoxifen Interplay with T3 in Male Rats: Pharmacologically Distinct Classes of Estrogen Responses Affecting Growth, Bone, and Lipid Metabolism, and Their Relation to Serum GH and IGF-I Endocrinology, October 1, 2001; 142(10): 4223 - 4235. [Abstract] [Full Text] [PDF]

				M. RUDLING and B. ANGELIN Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice FASEB J, June 1, 2001; 15(8): 1350 - 1356. [Abstract] [Full Text] [PDF]

				D. Linden, A. Sjoberg, L. Asp, L. Carlsson, and J. Oscarsson Direct effects of growth hormone on production and secretion of apolipoprotein B from rat hepatocytes Am J Physiol Endocrinol Metab, December 1, 2000; 279(6): E1335 - E1346. [Abstract] [Full Text] [PDF]

				Discontinuation of Growth Hormone (GH) Treatment: Metabolic Effects in GH-Deficient and GH-Sufficient Adolescent Patients Compared with Control Subjects J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4516 - 4524. [Abstract] [Full Text]

				B.-A. Bengtsson, R. Abs, H. Bennmarker, J. P. Monson, U. Feldt-Rasmussen, E. Hernberg-Ståhl, B. Westberg, P. Wilton, and C. Wüster The Effects of Treatment and the Individual Responsiveness to Growth Hormone (GH) Replacement Therapy in 665 GH-Deficient Adults J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3929 - 3935. [Abstract] [Full Text]

				M. Leonsson, J. Oscarsson, I. Bosaeus, B. K. Lundgren, G. Johannsson, O. Wiklund, and B. A. Bengtsson Growth Hormone (GH) Therapy in GH-Deficient Adults Influences the Response to a Dietary Load of Cholesterol and Saturated Fat in Terms of Cholesterol Synthesis, But Not Serum Low Density Lipoprotein Cholesterol Levels J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1296 - 1303. [Abstract] [Full Text]

				P. Parini, B. Angelin, and M. Rudling Cholesterol and Lipoprotein Metabolism in Aging : Reversal of Hypercholesterolemia by Growth Hormone Treatment in Old Rats Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 832 - 839. [Abstract] [Full Text] [PDF]

				L. Carlsson, I. Nilsson, and J. Oscarsson Hormonal Regulation of Liver Fatty Acid-Binding Protein in Vivo and in Vitro: Effects of Growth Hormone and Insulin Endocrinology, June 1, 1998; 139(6): 2699 - 2709. [Abstract] [Full Text] [PDF]

				G. P. Ceda, E. Dall’Aglio, A. Magnacavallo, N. Vargas, V. Fontana, M. Maggio, G. Valenti, P. D. K. Lee, R. L. Hintz, and A. R. Hoffman The Insulin-Like Growth Factor Axis and Plasma Lipid Levels in the Elderly J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 499 - 502. [Abstract] [Full Text]

				G. Johannsson, P. Marin, L. Lonn, M. Ottosson, K. Stenlof, P. Bjorntorp, L. Sjostrom, and B.-A. Bengtsson Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 727 - 734. [Abstract] [Full Text] [PDF]